A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Minocin® (Minocycline) for Infections Caused by Gram-negative Bacteria in a Real World Setting

NCT03160040 · clinicaltrials.gov ↗

COMPLETED

Status

71

Enrollment

INDUSTRY

Sponsor class

Conditions

Gram-Negative Bacterial Infections

Interventions

DRUG: Minocycline IV

Sponsor

Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)